Calidi Biotherapeutics Overview
Latest ROE for Calidi Biotherapeutics: -748.64% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-748.64%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for CLDI is -748.64%. That is below the sector sector average of 11.73%. Investors often review this figure alongside Calidi Biotherapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, CLDI currently prints -748.64% for ROE, while the sector average sits near 11.73%. That is roughly 6480.2% below the sector mean. Large gaps often invite a closer look at Calidi Biotherapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Calidi Biotherapeutics converts resources into returns. At -748.64%, CLDI may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting CLDI's ROE (-748.64%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
